Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Item
http://www.wikidata.org/entity/Q37871666
Heme oxygenase-1 prevents cardiac dysfunction in streptozotocin-diabetic mice by reducing inflammation, oxidative stress, apoptosis and enhancing autophagyPathological ventricular remodeling: therapies: part 2 of 2.Intracellular Signaling Pathways in Rheumatoid ArthritisAutoimmunity in 2011.Caspase-3 as a therapeutic target for heart failure.Clinical outcomes and management of inflammatory bowel disease in the older patient.Current immunotherapy in rheumatoid arthritis.Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target?Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis.Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.
P2860

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Item
http://www.wikidata.org/entity/Q37871666
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
@en
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
@nl
type
label
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
@en
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
@nl
prefLabel
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
@en
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues
@en
P2093
P304
P31
P356
10.1016/J.AUTREV.2011.04.014
P433
P478
P50
P577
P5875
P698
P921